- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 277/06 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 277/06
Total number of patents in this class: 98
10-year publication summary
|
12
|
8
|
6
|
6
|
4
|
6
|
6
|
2
|
6
|
1
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Epics Therapeutics | 24 |
7 |
| Araris Biotech Ltd | 9 |
6 |
| Merck Serono SA | 103 |
5 |
| Ajinomoto Co., Inc. | 2275 |
4 |
| Cancer Research Technology, LLC | 5 |
4 |
| Pusan National University Industry-University Cooperation Foundation | 737 |
4 |
| The University of Melbourne | 559 |
4 |
| The Regents of the University of California | 20590 |
3 |
| Genentech, Inc. | 4090 |
3 |
| Xenon Pharmaceuticals Inc. | 195 |
3 |
| BASF SE | 21165 |
2 |
| Massachusetts Institute of Technology | 10204 |
2 |
| Abbvie Inc. | 1837 |
2 |
| Cancer Research Technologies LLC | 2 |
2 |
| Jiangsu Jibeier Pharmaceutical Co. Ltd. | 9 |
2 |
| Sanofi | 4274 |
2 |
| ATEN Porus Lifesciences Pvt. Ltd. | 5 |
2 |
| Novartis AG | 10338 |
1 |
| Hoffmann-La Roche Inc. | 3726 |
1 |
| Merck Sharp & Dohme Corp. | 2183 |
1 |
| Other owners | 38 |